Bae, 3,441 patient HCQ prophylaxis PSM study: 30% fewer cases [p=0.18] https://c19p.org/bae
copied to clipboard
Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea
et al., Viruses 2021, doi:10.3390/v13020329
Retrospective database analysis of prior HCQ usage in South Korea, showing non-statistically significantly lower mortality and cases with treatment.
|
risk of case, 30.3% lower, RR 0.70, p = 0.18, treatment 16 of 743 (2.2%), control 91 of 2,698 (3.4%), NNT 82, odds ratio converted to relative risk, PSM.
|
|
risk of case, 19.5% lower, RR 0.81, p = 0.50, treatment 16 of 743 (2.2%), control 91 of 2,698 (3.4%), odds ratio converted to relative risk, PSM, adjusted for region.
|
|
risk of case, 30.3% lower, RR 0.70, p = 0.30, treatment 16 of 743 (2.2%), control 91 of 2,698 (3.4%), NNT 82, odds ratio converted to relative risk, PSM, adjusted for immunosuppresant use.
|
|
risk of case, 40.2% lower, RR 0.60, p = 0.09, odds ratio converted to relative risk, PSM, HCQ >= 6 months.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Bae et al., 2/20/2021, retrospective, propensity score matching, South Korea, Asia, peer-reviewed, 8 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.